ELAN vs PAHC vs CHWY Stock Comparison

Elanco Animal Health, Phibro Animal Health and Chewy Prices as of Oct 29, 2026 Peers: Industry group
CHWY Chewy, Inc.
$20.84 +14.1% 1M -37.9% 1Y
Market cap
$8.62B
P/E
31.5x
Revenue (TTM)
$13.07B
Div. yield
–
Packaged Foods Consumer Staples
2 wins

Head to Head

11 decided of 12

Phibro Animal Health leads on 6 of the 12 questions below (Phibro Animal Health 6, Elanco Animal Health 3, Chewy 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionELANPAHCCHWYLeader
Larger companyMarket capitalisation $11.51B $1.57B $8.62B ELAN
Cheaper on earningsLower P/E, profitable companies only -57.9x 15.8x 31.5x PAHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.3x 11.4x 27.4x PAHC
Faster revenue growthRevenue growth, trailing twelve months +12.0% +17.1% +5.9% PAHC
More profitableNet margin, trailing twelve months -4.0% 6.6% 2.1% PAHC
Better return on capitalReturn on invested capital 6.1% 14.2% — PAHC
Less leveragedLower net debt / EBITDA 2.5x 2.1x 0.0x CHWY
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% –
Better 1-year returnPrice return, last 12 months +2.9% -5.7% -37.9% ELAN
Better 5-year returnAnnualised price return, 5 years -6.7%/yr +12.1%/yr -22.8%/yr PAHC
Less volatileAnnualised volatility, 1 year 42.3% 55.6% 47.3% ELAN
Higher overall scoreMean of the five percentile scores vs peers 66/100 68/100 68/100 CHWY

Percentile Scorecard

ELANPAHCCHWY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisELANPAHCCHWY
Valuation 94 #39 of 624 92 #51 of 624 57 #20 of 45
Growth 56 #265 of 601 85 #89 of 601 90 #5 of 42
Profitability 84 #89 of 541 85 #81 of 541 56 #18 of 40
Financial Health 32 #441 of 647 26 #481 of 647 59 #20 of 47
Shareholder Returns – 53 #169 of 359 80 #7 of 31
Overall 66 68 68
  • ELAN ranked among 671 companies in Pharmaceuticals and Biotechnology
  • PAHC ranked among 671 companies in Pharmaceuticals and Biotechnology
  • CHWY ranked among 48 companies in Branded Foods

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodELANPAHCCHWYSPY
1 month +2.8%+9.6%+14.1% +0.7%
3 months -12.2%+6.6%-8.8% +3.7%
6 months +3.9%-26.9%-18.0% +7.1%
Year to date +2.7%+4.0%-36.9% +12.8%
1 year +2.9%-5.7%-37.9% +11.9%
3 years +163.8%+255.2%+12.2% +85.2%
3 years, per year +38.2%+52.6%+3.9% +22.8%
5 years -29.3%+77.1%-72.5% +67.6%
5 years, per year -6.7%+12.1%-22.8% +10.9%
10 years —+49.2%— +262.0%
10 years, per year —+4.1%— +13.7%

Risk

MeasureELANPAHCCHWYSPY
Volatility, 1Y 42.3%55.6%47.3% 12.7%
Downside volatility, 1Y 42.8%60.0%48.2% 12.6%
Beta vs S&P 500, 1Y 1.290.740.77 1.00
Return / volatility, 1Y 0.07-0.10-0.80 0.94
Max drawdown, 5Y -76.3%-57.9%-81.2% -25.4%
From 52-week high -13.4%-34.8%-41.1% -1.2%
52-week high $26.84$59.58$35.37 $779.14
52-week low $19.80$28.52$17.51 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleELANPAHCCHWY
P/E now vs peer median -58.3xmedian 17.8x 15.8xmedian 17.8x 30.9xmedian 18.4x
P/S now vs peer median 2.3xmedian 9.1x 1.0xmedian 9.1x 0.6xmedian 0.7x
EV/EBITDA now vs peer median 11.3xmedian 15.0x 8.3xmedian 15.0x 17.7xmedian 12.0x
P/FCF now vs peer median 30.6xmedian 21.7x 159.7xmedian 21.7x 14.7xmedian 13.6x
P/B now vs peer median 1.8xmedian 2.2x 4.1xmedian 2.2x 22.6xmedian 1.6x
PEG now vs peer median 2.96median 0.35 0.35median 0.35 0.40median 0.55

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsELANPAHCCHWY
Revenue $5.02B $1.52B $13.07B
Gross profit $2.78B $512.52M $3.91B
Operating income $637.00M $194.40M $328.20M
Net income -$199.00M $99.72M $273.70M
Free cash flow $379.00M $9.87M $568.10M
R&D $371.00M – –
EPS (diluted) $-0.39 $2.43 $0.67
Cash & equivalents $530.00M $61.42M $611.00M
Total debt $3.92B $2.49B $591.70M
Shares (diluted) 505.90M 40.96M 410.10M
Enterprise value $9.50B $1.25B $5.91B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricELANPAHCCHWY
P/E -58.3x 15.8x 30.9x
P/FCF 30.6x 159.7x 14.7x
P/Operating cash flow 18.8x 22.9x 11.7x
P/S 2.3x 1.0x 0.6x
P/B 1.8x 4.1x 22.6x
P/Tangible book 3.4x 4.4x 37.9x
EV/EBITDA 11.3x 8.3x 17.7x
EV/EBIT 23.5x 10.9x 25.4x
EV/Revenue 3.0x 1.4x 0.6x
EV/FCF 39.6x 213.9x 14.7x
EV/Operating cash flow 24.3x 30.6x 11.6x
PEG (3Y EPS CAGR) 2.96 0.35 0.40

Growth

14 metrics
MetricELANPAHCCHWY
Revenue growth (1Y) 12.0% 17.1% 5.9%
Revenue CAGR (3Y) 5.1% 15.8% 6.4%
Gross profit growth (1Y) 13.2% 28.1% 7.6%
Gross profit CAGR (3Y) 3.9% 19.8% 8.5%
Operating income growth (1Y) 22.0% 76.0% 102.0%
Operating income CAGR (3Y) 59.8% 39.3% 139.1%
Net income growth (1Y) -145.9% 106.6% 81.1%
Net income CAGR (3Y) -20.8% 45.2% 73.8%
EPS growth (1Y) -145.3% 105.2% 89.2%
EPS CAGR (3Y) -19.7% 44.6% 76.8%
Operating cash flow growth (1Y) 7.9% -13.9% 17.3%
Operating cash flow CAGR (3Y) 73.6% 73.0% 10.9%
Free cash flow growth (1Y) 5.0% -76.4% 22.7%
Free cash flow CAGR (3Y) 101.8% 31.2% 18.6%

Profitability

14 metrics
MetricELANPAHCCHWY
Gross margin 55.4% 33.8% 29.9%
EBITDA margin 26.5% 16.8% 3.6%
Operating margin 12.7% 12.8% 2.5%
Pretax margin -3.3% 9.0% 2.7%
Net margin -4.0% 6.6% 2.1%
FCF margin 7.5% 0.6% 4.3%
Operating cash flow margin 12.3% 4.5% 5.5%
Return on equity -3.0% 26.7% 68.9%
Return on assets -1.5% 6.8% 7.8%
Return on invested capital 6.1% 14.2% –
Return on capital employed 5.5% 16.8% 24.9%
Asset turnover 0.4x 1.0x 3.7x
Cash conversion (OCF / net income) -3.1x 0.7x 2.6x
Stock comp / revenue 1.5% 0.1% 2.3%

Financial Health

11 metrics
MetricELANPAHCCHWY
Debt / assets 28.9% 41.1% 15.8%
Debt / equity 0.6x 1.6x 1.6x
Net debt / EBITDA 2.5x 2.1x 0.0x
Debt / FCF 10.3x 62.5x 1.0x
Liabilities / assets 51.4% 74.3% 90.1%
Equity / assets 48.6% 25.7% 9.9%
Interest coverage 2.6x 4.2x –
Current ratio 2.1x 3.0x 0.8x
Quick ratio 0.9x 1.1x 0.4x
Cash ratio 0.3x 0.3x 0.3x
Altman Z-score 1.48 3.11 4.71

Shareholder Returns

7 metrics
MetricELANPAHCCHWY
Dividend yield – 1.2% –
Net buyback yield – – 6.1%
Shareholder yield – 1.2% 6.1%
Payout ratio (earnings) – 19.5% –
Payout ratio (FCF) – 197.3% –
Dividend growth (1Y) – 0.1% –
Dividend CAGR (3Y) – 0.0% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusELANPAHCCHWY
Forward P/E 21.3xFY2026 11.4xFY2027 27.4xFY2026
EPS, next fiscal year $1.09FY2026 $3.42FY2027 $0.76FY2026
EPS growth, next FY +16.0%FY2026 +6.2%FY2027 +46.2%FY2026
EPS growth, the year after +23.9% +9.6% +47.4%
Revenue, next fiscal year $4.79BFY2026 $1.53BFY2027 $12.87BFY2026
Revenue growth, next FY +1.6%FY2026 +0.6%FY2027 +2.1%FY2026
Revenue growth, the year after +19.7% -0.2% +5.5%
ELAN estimates →PAHC estimates →CHWY estimates →

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersELANPAHCCHWY
Held by institutions 100.0% 51.5% 100.0%
Institutions holding 524 209 512
Change in shares held, QoQ +4.4% +3.0% -0.4%
Institutions buying 246 117 278
Institutions selling 210 74 155
Buyers to sellers 1.17 1.58 1.79
ELAN holders →PAHC holders →CHWY holders →

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ELANPAHCCHWY
ELAN 1.00 0.51 0.24
PAHC 0.51 1.00 0.20
CHWY 0.24 0.20 1.00

Add a Peer

Largest companies in the same industry
ELAN · Animal Health
+MRKMerck +CORCencora +IDXXIdexx Laboratories +ZTSZoetis +NEOGNeogen +BFLYButterfly Network +ANIKAnika Therapeutics +ICCCImmucell
Plot all 33 Animal Health stocks → Plot all 92 Packaged Foods stocks →

Related Comparisons

ELAN vs MRKMerck ELAN vs CORCencora ELAN vs IDXXIdexx Laboratories ELAN vs ZTSZoetis

Frequently Asked Questions

Which is bigger, ELAN, PAHC and CHWY?

Elanco Animal Health (ELAN) is the largest by market capitalisation: Elanco Animal Health (ELAN) $11.51B, Phibro Animal Health (PAHC) $1.57B, Chewy (CHWY) $8.62B.

Which stock is cheaper, ELAN, PAHC and CHWY?

Phibro Animal Health (PAHC) trades on the lowest price-to-earnings ratio (Elanco Animal Health (ELAN) -57.9x, Phibro Animal Health (PAHC) 15.8x, Chewy (CHWY) 31.5x). On next year's consensus earnings, Phibro Animal Health (PAHC) is cheapest (Elanco Animal Health (ELAN) 21.3x, Phibro Animal Health (PAHC) 11.4x, Chewy (CHWY) 27.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Phibro Animal Health (PAHC) grew revenue fastest over the trailing twelve months: Elanco Animal Health (ELAN) +12.0%, Phibro Animal Health (PAHC) +17.1%, Chewy (CHWY) +5.9%.

Which company is more profitable?

Phibro Animal Health (PAHC) has the highest net margin (Elanco Animal Health (ELAN) -4.0%, Phibro Animal Health (PAHC) 6.6%, Chewy (CHWY) 2.1%). On return on invested capital, Phibro Animal Health (PAHC) leads (Elanco Animal Health (ELAN) 6.1%, Phibro Animal Health (PAHC) 14.2%).

Which stock has performed better?

Over the past year Elanco Animal Health (ELAN) returned the most: Elanco Animal Health (ELAN) +2.9%, Phibro Animal Health (PAHC) -5.7%, Chewy (CHWY) -37.9%. Over five years, Phibro Animal Health (PAHC) compounded fastest (Elanco Animal Health (ELAN) -6.7%/yr, Phibro Animal Health (PAHC) +12.1%/yr, Chewy (CHWY) -22.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Elanco Animal Health (ELAN) 0.00%, Phibro Animal Health (PAHC) 0.01%, Chewy (CHWY) 0.00%. Elanco Animal Health (ELAN) and Chewy (CHWY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Elanco Animal Health (ELAN) has been the steadiest (Elanco Animal Health (ELAN) 42.3%, Phibro Animal Health (PAHC) 55.6%, Chewy (CHWY) 47.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ELAN, PAHC and CHWY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Phibro Animal Health (PAHC) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.